Please login to the form below

edoxaban

This page shows the latest edoxaban news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

Xarelto no better than aspirin in secondary stroke study

Savaysa (edoxaban) some way behind in third and fourth place, respectively.
Xarelto beats aspirin for recurrent blood clots

edoxaban). Xarelto has slipped from a 60%-plus market share, however, with Eliquis gaining ground in part because of a debate about Xarelto's role in stroke prevention and the design
Portola rejection hands advantage to Boehringer's Pradaxa

Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.
Boehringer starts to feel impact of Spiriva generics

Squibb's Eliquis (apixaban) and Daiichi Sankyo's recently-approved Savaysa (edoxaban).
BMS claims 80% market share for Opdivo in US

and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery. ... Daiichi Sankyo is conducting a large, worldwide, phase III trial of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Scientific Director: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Market Access Consultant - Greater Manchester: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Healthcare PR Senior Account Manager: Salary TBC

Sudler London - Account Director: Competitive

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Graduate Scientific Editor: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Medical Writer - Creative and Scientific Projects: DOE

Account Director or Senior Account Director: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Subscribe to our email news alerts

PMHub

Add my company

Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....